The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Audeo Oncology's quick ratio for the quarter that ended in Sep. 2012 was 1.33.
Audeo Oncology has a quick ratio of 1.33. It generally indicates good short-term financial strength.
The historical rank and industry rank for Audeo Oncology's Quick Ratio or its related term are showing as below:
AURX's Quick Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.33 * Ranked among companies with meaningful Quick Ratio only.
Audeo Oncology Quick Ratio Historical Data
The historical data trend for Audeo Oncology's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Audeo Oncology Quick Ratio Chart
Audeo Oncology Annual Data
Trend
Jun10
Jun11
Jun12
Quick Ratio
0.01
0.01
3.54
Audeo Oncology Quarterly Data
Jun11
Mar12
Jun12
Sep12
Quick Ratio
0.01
0.03
3.54
1.33
Competitive Comparison of Audeo Oncology's Quick Ratio
For the Drug Manufacturers - General subindustry, Audeo Oncology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Audeo Oncology's Quick Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Audeo Oncology's Quick Ratio falls into.
Audeo Oncology Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Audeo Oncology's Quick Ratio for the fiscal year that ended in Jun. 2012 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Audeo Oncology (DELISTED:AURX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Audeo Oncology Quick Ratio Related Terms
Thank you for viewing the detailed overview of Audeo Oncology's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Audeo Oncology (Audeo Oncology) Business Description
Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DELISTED:AURX has been successfully added to your